Literature DB >> 20234195

Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2.

Joseph B Margolick, Hejab Imteyaz, Joel E Gallant, Susan J Langan, Jason B Dinoso, Janet Siliciano, Joel Blankson, Tricia L Nilles, Kendall A Smith, Linda G Apuzzo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20234195      PMCID： PMC4565498          DOI： 10.1097/QAD.0b013e328333adfb

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  13 in total

1.  Immune control of HIV-1 after early treatment of acute infection.

Authors:  E S Rosenberg; M Altfeld; S H Poon; M N Phillips; B M Wilkes; R L Eldridge; G K Robbins; R T D'Aquila; P J Goulder; B D Walker
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

2.  Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.

Authors:  Mark Dybul; Bertha Hidalgo; Tae-Wook Chun; Michael Belson; Stephen A Migueles; Jesse S Justement; Betsey Herpin; Cheryl Perry; Claire W Hallahan; Richard T Davey; Julia A Metcalf; Mark Connors; Anthony S Fauci
Journal:  J Infect Dis       Date:  2001-12-14       Impact factor: 5.226

3.  Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.

Authors:  J P Lalezari; J A Beal; P J Ruane; C J Cohen; E L Jacobson; D Sundin; W P Leong; S P Raffanti; D A Wheeler; R D Anderson; P Keiser; S R Schrader; J C Goodgame; C R Steinhart; R L Murphy; M J Wolin; K A Smith
Journal:  HIV Clin Trials       Date:  2000 Nov-Dec

4.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

5.  Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.

Authors:  Cécile Goujard; Fabienne Marcellin; Houria Hendel-Chavez; Marianne Burgard; Vincent Meiffrédy; Alain Venet; Christine Rouzioux; Yacine Taoufik; Raphaëlle El Habib; Maria Beumont-Mauviel; Jean-Pierre Aboulker; Yves Lévy; Jean-François Delfraissy
Journal:  AIDS Res Hum Retroviruses       Date:  2007-09       Impact factor: 2.205

6.  Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo.

Authors:  Joseph N Blattman; Jason M Grayson; E John Wherry; Susan M Kaech; Kendall A Smith; Rafi Ahmed
Journal:  Nat Med       Date:  2003-04-14       Impact factor: 53.440

7.  Interleukin-2 therapy in patients with HIV infection.

Authors:  D Abrams; Y Lévy; M H Losso; A Babiker; G Collins; D A Cooper; J Darbyshire; S Emery; L Fox; F Gordin; H C Lane; J D Lundgren; R Mitsuyasu; J D Neaton; A Phillips; J P Routy; G Tambussi; D Wentworth
Journal:  N Engl J Med       Date:  2009-10-15       Impact factor: 91.245

8.  Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection.

Authors:  B Martinez-Mariño; B M Ashlock; S Shiboski; F M Hecht; J A Levy
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

9.  HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.

Authors:  Asier Sáez-Cirión; Christine Lacabaratz; Olivier Lambotte; Pierre Versmisse; Alejandra Urrutia; Faroudy Boufassa; Françoise Barré-Sinoussi; Jean-François Delfraissy; Martine Sinet; Gianfranco Pancino; Alain Venet
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-11       Impact factor: 11.205

10.  Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial.

Authors:  Kendall A Smith; Sofija Andjelic; Zoran Popmihajlov; Liza Kelly-Rossini; Aquanette Sass; Martin Lesser; Steven Benkert; Cory Waters; Joyce Ruitenberg; Paul Bellman
Journal:  PLoS Clin Trials       Date:  2007-01-26
View more
  4 in total

Review 1.  Developing strategies for HIV-1 eradication.

Authors:  Christine M Durand; Joel N Blankson; Robert F Siliciano
Journal:  Trends Immunol       Date:  2012-08-03       Impact factor: 16.687

2.  Prolonged control of an HIV type 1 escape variant following treatment interruption in an HLA-B*27-positive patient.

Authors:  Karen A O'Connell; Robert K Pelz; Jason B Dinoso; Eric Dunlop; John Paik-Tesch; Thomas M Williams; Joel N Blankson
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09-21       Impact factor: 2.205

3.  Late-emerging strains of HIV induce T-cell homeostasis failure by promoting bystander cell death and immune exhaustion in naïve CD4 and all CD8 T-cells.

Authors:  Catherine N Kibirige; Frederick A Menendez; Hao Zhang; Tricia L Nilles; Susan Langan; Joseph B Margolick
Journal:  Med Hypotheses       Date:  2014-04-13       Impact factor: 1.538

4.  Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.

Authors:  Maria Salgado; S Alireza Rabi; Karen A O'Connell; Robert W Buckheit; Justin R Bailey; Amina A Chaudhry; Autumn R Breaud; Mark A Marzinke; William Clarke; Joseph B Margolick; Robert F Siliciano; Joel N Blankson
Journal:  Retrovirology       Date:  2011-12-05       Impact factor: 4.602
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.